FDA Clearance Tracker · P990027-S002
TECHNOLAS 217A EXCIMER LASER SYSTEM
Last checked: Nov 20, 2026Latest source record: May 17, 2002 (this decision)Source: openFDAMethods & limitations
Decided
May 17, 2002
Approved
Time to decision
539 days
Received Nov 24, 2000. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P990027-S002
- Device name
- TECHNOLAS 217A EXCIMER LASER SYSTEM
- Applicant
- Technolas Perfect Vision GmbH
- Applicant location
- MüNchen
- Received
- Nov 24, 2000
- Decided
- May 17, 2002
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P990027
Device type
- Device type
- Excimer laser system (LZS)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
APPROVAL THE TECHNOLAS 217A EXCIMER LASER SYSTEM. THIS DEVICE IS INDICATED FOR LASER IN-SITU KERATOMILEUSIS (LASIK) TREATMENTS: 1) FOR THE REDUCTION OR ELIMINATION OF MYOPIC ASTIGMATISM UP TO -12.00 D MRSE, WITH SPHERE BETWEEN >-7.00 D TO -10.99 D AND CYLINDER BETWEEN 0.00 AND <-3.00 D; 2) IN PATIENTS WITH DOCUMENTED EVIDENCE OF A CHANGE IN MANIFEST REFRACTION OF LESS THAN OR EQUAL TO 0.50 DIOPTERS (IN BOTH CYLINDER AND SPHERE COMPONENTS) FOR AT LEAST ONE YEAR PRIOR TO THE DATE OF THE PRE-OPERATIVE EXAMINATION; AND, 3) IN PATIENTS WHO ARE 21 YEARS OF AGE OR OLDER.
Source documents
Other decisions for Technolas Perfect Vision GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- TECHNOLAS TENEO 317 (MODEL 2) Excimer Laser SystemPMA supplement
P990027-S021 · Decided Nov 22, 2023 · 293 days after receipt · Panel Track
Device type: Excimer laser system (LZS) · Ophthalmology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.